Literature DB >> 32250468

Movement Disorders in the World of COVID-19.

A Jon Stoessl1, Kailash P Bhatia2, Marcello Merello3.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32250468     DOI： 10.1002/mds.28069

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


× No keyword cloud information.
  13 in total

1.  Neurologic Manifestations of COVID-19.

Authors:  Farnaz Delavari; Farnaz Najmi Varzaneh; Nima Rezaei
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

2.  Is Telemedicine the New Normal or Is the Office Visit Still the Movement Disorder Option of Choice?

Authors:  Christopher G Goetz; Glenn T Stebbins
Journal:  Mov Disord       Date:  2021-07-09       Impact factor: 9.698

3.  Mental Health, Physical Activity, and Quality of Life in Parkinson's Disease During COVID-19 Pandemic.

Authors:  Ali Shalash; Tamer Roushdy; Mohamed Essam; Mai Fathy; Noha L Dawood; Eman M Abushady; Hanan Elrassas; Asmaa Helmi; Eman Hamid
Journal:  Mov Disord       Date:  2020-06-07       Impact factor: 10.338

Review 4.  How COVID-19 will boost remote exercise-based treatment in Parkinson's disease: a narrative review.

Authors:  Agnes Langer; Lucia Gassner; Anna Flotz; Sebastian Hasenauer; Jakob Gruber; Laurenz Wizany; Rochus Pokan; Walter Maetzler; Heidemarie Zach
Journal:  NPJ Parkinsons Dis       Date:  2021-03-08

5.  A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey.

Authors:  Katie McGoohan; Anneesa Amjad; Natasha Ratcliffe; Sagnik Bhattacharyya; Gillian Granville; Matthew Sullivan; Lesley Gosden; Dag Aarsland; K Ray Chaudhuri; Dominic Ffytche; Clive Ballard; Latha Velayudhan
Journal:  Front Psychiatry       Date:  2020-12-23       Impact factor: 4.157

6.  The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism.

Authors:  Caroline M Tanner; Steven R Cummings; Michael A Schwarzschild; Ethan G Brown; E Ray Dorsey; Alberto J Espay; Nicholas B Galifianakis; Samuel M Goldman; Irene Litvan; Nijee Luthra; Nikolaus R McFarland; Kyle T Mitchell; David G Standaert; Douglas C Bauer; Susan L Greenspan; James C Beck; Kenneth W Lyles
Journal:  NPJ Parkinsons Dis       Date:  2021-03-01

7.  Potential impact of COVID-19 on ongoing clinical trials: a simulation study with the neurological Yale Global Tic Severity Scale based on the CANNA-TICS study.

Authors:  Florian Lasch; Lorenzo Guizzaro; Lukas Aguirre Dávila; Kirsten Müller-Vahl; Armin Koch
Journal:  Pharm Stat       Date:  2021-02-16       Impact factor: 1.234

8.  The Challenge of Managing Parkinson's Disease Patients during the COVID-19 Pandemic.

Authors:  Divyani Garg; Rajinder K Dhamija
Journal:  Ann Indian Acad Neurol       Date:  2020-04-20       Impact factor: 1.383

9.  Virtual Parkinson's Disease Support Groups in the COVID-19 Era: Social Connection in the Time of Social Distancing.

Authors:  Indu Subramanian
Journal:  Mov Disord Clin Pract       Date:  2020-07-10

Review 10.  Effects of COVID-19 on Parkinson's Disease Clinical Features: A Community-Based Case-Control Study.

Authors:  Roberto Cilia; Salvatore Bonvegna; Giulia Straccia; Nico Golfrè Andreasi; Antonio E Elia; Luigi M Romito; Grazia Devigili; Emanuele Cereda; Roberto Eleopra
Journal:  Mov Disord       Date:  2020-06-11       Impact factor: 9.698
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.